Strand Life Sciences Develops Prenatal Genomic Diagnostics Portfolio The best-in-class portfolio of prenatal screening uses Strand’s advanced capabilities in genomic

Strand Life Sciences, a subsidiary of Reliance Industries Ltd., and a leading global provider of genomic and bioinformatic solutions, proudly announces its prenatal screening and diagnostics portfolio with two breakthrough technologies: CNSeq (for identification of aneuploidies and copy number variations) and MaatriSeq (Non-Invasive Prenatal Screening). These innovations are tailored to the specific needs of the Indian community, offering unparalleled efficiency, costeffectiveness, and accuracy.

CNSeq brings the latest Next Generation Sequencing technology to an important prenatal test marking a significant leap forward in prenatal diagnostics. Leveraging proprietary software, CNSeq delivers unmatched precision in identifying Copy Number Variations (CNVs), outperforming traditional cytogenetic and molecular techniques.

MaatriSeq is the first Non-Invasive Prenatal Screening (NIPS) solution to be validated on the latest high throughput Illumina NovaSeqTM X Plus sequencing platform to deliver a highly accurate and cost-effective solution making it accessible to a wider community in India. MaatriSeq exhibits exceptional sensitivity and specificity in identifying fetal chromosomal abnormalities, surpassing other existing techniques.

These advanced tests developed by Strand Life Sciences are based on a genomic analysis pipeline specifically developed and validated on Indian samples and conditions. “Strand is at the forefront of advanced genomic solutions and continues to redefine standards in genetic diagnostics. With these innovations in advanced genetic technologies, Strand wants to contribute to the efforts by the Indian Government in reducing the burden of rare diseases in India,” said Ramesh Hariharan, CEO and Cofounder of Strand Life Sciences.